Storia in 2 fonti

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.

Raccontata da

forbes.com

theguardian.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

forbes.comStai leggendo3 g fa

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.

originale

theguardian.com1 g fa

Is the growing use of GLP-1s reshaping ideas of Black beauty?

People across the Black diaspora are increasingly turning to weight-loss drugs. How might this reshape our health, wellbeing and body image?

Leggi questa versione → originale

Timeline cronologica

martedì 9 giugno 2026·forbes.com
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.
mercoledì 10 giugno 2026·theguardian.com
Is the growing use of GLP-1s reshaping ideas of Black beauty?
People across the Black diaspora are increasingly turning to weight-loss drugs. How might this reshape our health, wellbeing and body image?